Previous 10 | Next 10 |
2023-05-01 16:51:05 ET Summary The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-year returns. 40 portfolios have been formed sin...
2023-04-28 13:00:00 ET Summary I will introduce you to 10 companies that provide investors with a relatively high Dividend Yield and which I consider attractive to invest in. On Average, the selected companies have a Dividend Yield [TTM] of 5.43%. Moreover, they have shown an Aver...
2023-04-27 13:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-27 10:07:00 ET The pharmaceutical industry is among the most profitable in the entire investment universe. This is because drug patents give drugmakers practical monopolies for long periods of time before those patents expire and competition is allowed by regulators. But that's ...
2023-04-27 06:34:36 ET A committee of the European Medicines Agency (EMA) recommended the approval of Novartis ( NYSE: NVS ) Cosentyx (secukinumab) to treat adults with active moderate to severe hidradenitis suppurativa (HS). HS is a condition in which small, painful lump...
2023-04-26 13:09:44 ET Summary Novartis delivered very strong Q1 results. Sandoz spin-off is advancing, but there were no major details. The company raised its FY outlook. Despite that EPS growth is likely limited and Novartis valuations look full. Novartis ( NVS ...
2023-04-26 11:32:44 ET Eli Lilly ( NYSE: LLY ) is expected to report its Q1 2023 results before the opening bell on Thursday for a market on the lookout for updates on its pipeline led by Alzheimer’s candidate donanemab and weight loss agent tirzepatide. Amid waning deman...
2023-04-25 10:47:07 ET Novartis AG (NVS) Q1 2023 Earnings Conference Call April 25, 2023 08:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference...
2023-04-25 08:40:12 ET Summary Novartis reported strong Q1 2023 results, beating the analyst EPS and revenue consensus. Both innovative products and the Sandoz business unit performed well. Novartis increased the full-year revenue and earnings guidance after the strong perform...
2023-04-25 08:21:25 ET The following slide deck was published by Novartis AG in conjunction with their 2023 Q1 earnings call. For further details see: Novartis AG 2023 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...